Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...

Johnson Matthey Share Chat. Chat About JMAT Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary.

Poolbeg Pharma Share Chat. Chat About POLB Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary.

(Alliance News) - The FTSE 100 was called slightly higher on Monday, following news of US President Donald Trump's intention to wage a "crushing" financial operation against Iran. Eyes are also on US ...

GSK stock is trading higher after executive dividend reinvestment lifted ADS holdings, while fresh valuation analysis flags the shares as trading above estimated intrinsic value for US investors. GSK ...

GSK Plc agreed another deal with British biotech Relation Therapeutics Ltd. to use artificial intelligence to speed up drug development. The agreement, which could see Relation paid up to $110 million ...

Good afternoon, and welcome to this GSK Q2 Results and Accelerate Growth event. Today, we look forward to having a good event. And if we could have the agenda slide on the screen, please. Just a few ...

Two GlaxoSmithKline (GSK) R&D team members at work in the company’s Upper Merion, PA, laboratory. GSK has agreed to acquire Nuvalent for $10.6 billion, in a deal designed to strengthen the buyer’s ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. LONDON — GSK said Tuesday it would buy the ...

GSK GSK-1.07%decrease; down pointing triangle agreed to buy U.S. cancer-drug developer Nuvalent for $10.6 billion, the British pharmaceutical company’s latest move to bolster its oncology business.

(Alliance News) - GSK agrees to buy US cancer treatment firm Nuvalent for USD10.6 billion, AstraZeneca advances its own weight-loss treatment while Bellway reports an "increasingly challenging" ...